Compare Rivian Automotive, Inc. (RIVN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rivian Automotive, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Rivian Automotive, Inc. trades at $16.03 (market cap $23.17B), while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B). The key difference: Rivian Automotive, Inc. is far larger — about 13.3× Recursion Pharmaceuticals Inc's market cap, and Rivian Automotive, Inc. is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RIVN | RXRX | |
|---|---|---|
Market Cap | $23.17B | $1.74B |
Sector | Consumer Cyclical | Health |
52-Week High | $22.45 | $6.79 |
52-Week Low | $12.50 | $2.84 |
Enterprise Value | $23.22B | $1.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rivian Automotive (RIVN) trades at $16.17, up 2.73% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $18.70. The company continues to report significant net losses but has shown improvement in revenue growth and gross profit margins, while recent news highlights strong demand for the R2 SUV and advancements in autonomy capabilities.
The outlook for RIVN hinges on successful R2 production scaling and path to profitability, with upside potential from current levels but high execution risk amid competitive EV market pressures and persistent cash burn requiring ongoing financing.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, though it maintains partnerships with Genentech and Sanofi. Analyst consensus shows 40% buy ratings with institutional interest from CalSTRS increasing its stake by 64% in Q2 2026.
Outlook remains speculative with significant losses (-961.97% net margin) offset by AI-driven drug discovery potential. Key risks include cash burn and pipeline delays, while catalysts involve clinical progress. The stock offers high-risk growth exposure in TechBio, dependent on platform validation and partnership milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
